Bluejay Diagnostics (NASDAQ:BJDX) Shares Up 12.7%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX)’s share price shot up 12.7% on Monday . The company traded as high as $0.65 and last traded at $0.62. 41,154 shares changed hands during trading, a decline of 12% from the average session volume of 46,850 shares. The stock had previously closed at $0.55.

Bluejay Diagnostics Stock Down 12.0 %

The company has a market cap of $1.48 million, a PE ratio of -0.06 and a beta of 0.85. The company’s fifty day moving average is $0.75 and its 200-day moving average is $1.88.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($0.68) by ($1.10).

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Sabby Management LLC purchased a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,221 shares of the company’s stock, valued at approximately $92,000. Sabby Management LLC owned 1.71% of Bluejay Diagnostics at the end of the most recent reporting period. Institutional investors own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.